Home
FDA Approval of Johnson & Johnson ICOTYDE™ Ushers in New Era for First-Line Systemic Treatment of Plaque Psoriasis with a Targeted Oral Peptide

FDA Approval of Johnson & Johnson ICOTYDE™ Ushers in New Era for First-Line Systemic Treatment of Plaque Psoriasis with a Targeted Oral Peptide

Today’s Highlights March 18, 2026

Johnson & Johnson in the NEWS

March 18, 2026, Johnson & Johnson (JNJ) announced today that the FDA has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
March 18, 2026

Other Articles